U.S. Markets closed

Inhibikase Therapeutics, Inc. (IKT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.3300+0.0600 (+2.64%)
At close: 4:00PM EDT
2.3000 -0.03 (-1.29%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.2700
Open2.2200
Bid2.2800 x 2200
Ask2.3300 x 1100
Day's Range2.2001 - 2.3500
52 Week Range2.0300 - 11.8000
Volume292,272
Avg. Volume739,065
Market Cap58.561M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 17, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Inhibikase To Start Testing Its Parkinson's Candidate In Patients
    Benzinga

    Inhibikase To Start Testing Its Parkinson's Candidate In Patients

    The FDA has signed off Inhibikase Therapeutics Inc's (NASDAQ: IKT) Phase 1b extension study to evaluate its lead drug candidate IkT-148009 in Parkinson's patients. The randomized Phase 1 study investigated the safety, tolerability, and pharmacokinetics (PK) of IkT-148009 in healthy volunteers aged 45 to 70 years old. Forty-two patients were dosed with IkT-148009 between 12.5 and 100 mg with no clinically significant adverse events reported. High drug exposures were achieved in this dose range an

  • Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients
    PR Newswire

    Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients

    Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that, after a review of safety, tolerability and pharmacokinetic data from the Company's Phase 1 clinical trial of IkT-148009 in healthy volunteers, the United States Food and Drug Administration (FDA) has given the Company clearance to begin a Phase 1b extension study to evaluat

  • Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock
    PR Newswire

    Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock

    Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced the closing of its previously announced underwritten public offering of 15 million shares of its common stock at a price to the public of $3.00 per share. The gross proceeds to Inhibikase from the public offering, before deducting underwriting discounts and commi